Molecular Partners Ag Stock Market Value
| MOLN Stock | USD 3.73 0.12 3.12% |
| Symbol | Molecular |
Molecular Partners Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Molecular Partners. If investors know Molecular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Molecular Partners listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.12) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Molecular Partners' value and its price as these two are different measures arrived at by different means. Investors typically determine if Molecular Partners is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Molecular Partners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Molecular Partners 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Molecular Partners' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Molecular Partners.
| 06/23/2025 |
| 07/23/2025 |
If you would invest 0.00 in Molecular Partners on June 23, 2025 and sell it all today you would earn a total of 0.00 from holding Molecular Partners AG or generate 0.0% return on investment in Molecular Partners over 30 days. Molecular Partners is related to or competes with Climb Bio, Edgewise Therapeutics, Monte Rosa, Century Therapeutics, Lyell Immunopharma, MediciNova, and PepGen. Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and... More
Molecular Partners Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Molecular Partners' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Molecular Partners AG upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.31 | |||
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 22.81 | |||
| Value At Risk | (7.01) | |||
| Potential Upside | 6.94 |
Molecular Partners Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Molecular Partners' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Molecular Partners' standard deviation. In reality, there are many statistical measures that can use Molecular Partners historical prices to predict the future Molecular Partners' volatility.| Risk Adjusted Performance | 0.0403 | |||
| Jensen Alpha | 0.3393 | |||
| Total Risk Alpha | (0.81) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | (0.14) |
Molecular Partners Backtested Returns
Molecular Partners has Sharpe Ratio of -0.018, which conveys that the firm had a -0.018 % return per unit of risk over the last 3 months. Molecular Partners exposes thirty different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Molecular Partners' Risk Adjusted Performance of 0.0403, downside deviation of 4.31, and Mean Deviation of 3.02 to check out the risk estimate we provide. The company secures a Beta (Market Risk) of -0.97, which conveys possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning Molecular Partners are expected to decrease slowly. On the other hand, during market turmoil, Molecular Partners is expected to outperform it slightly. At this point, Molecular Partners has a negative expected return of -0.0697%. Please make sure to verify Molecular Partners' semi variance, and the relationship between the treynor ratio and daily balance of power , to decide if Molecular Partners performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.33 |
Poor reverse predictability
Molecular Partners AG has poor reverse predictability. Overlapping area represents the amount of predictability between Molecular Partners time series from 23rd of June 2025 to 8th of July 2025 and 8th of July 2025 to 23rd of July 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Molecular Partners price movement. The serial correlation of -0.33 indicates that nearly 33.0% of current Molecular Partners price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.33 | |
| Spearman Rank Test | 0.05 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Molecular Partners lagged returns against current returns
Autocorrelation, which is Molecular Partners stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Molecular Partners' stock expected returns. We can calculate the autocorrelation of Molecular Partners returns to help us make a trade decision. For example, suppose you find that Molecular Partners has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Molecular Partners regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Molecular Partners stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Molecular Partners stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Molecular Partners stock over time.
Current vs Lagged Prices |
| Timeline |
Molecular Partners Lagged Returns
When evaluating Molecular Partners' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Molecular Partners stock have on its future price. Molecular Partners autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Molecular Partners autocorrelation shows the relationship between Molecular Partners stock current value and its past values and can show if there is a momentum factor associated with investing in Molecular Partners AG.
Regressed Prices |
| Timeline |
Pair Trading with Molecular Partners
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Molecular Partners position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Molecular Partners will appreciate offsetting losses from the drop in the long position's value.Moving against Molecular Stock
| 0.68 | NUVL | Nuvalent | PairCorr |
| 0.65 | VRDN | Viridian Therapeutics | PairCorr |
| 0.65 | VTYX | Ventyx Biosciences | PairCorr |
| 0.64 | ACLX | Arcellx | PairCorr |
| 0.61 | PTAIF | PT Astra International Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Molecular Partners could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Molecular Partners when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Molecular Partners - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Molecular Partners AG to buy it.
The correlation of Molecular Partners is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Molecular Partners moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Molecular Partners moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Molecular Partners can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Molecular Partners Correlation, Molecular Partners Volatility and Molecular Partners Alpha and Beta module to complement your research on Molecular Partners. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Molecular Partners technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.